Healthcare Industry News: Heat shock protein
News Release - August 23, 2007
MitoPharm's Compound, Schisandrin B, Has Been Shown to Protect the Liver Against Chemical Toxin-Induced Damage
The Report Supports the Use of Schisandrin B as an Agent to Safeguard Liver Health Is Supported by Published Research and Is Corroborated by the Long History of Schisandra as a Liver TonicSEATTLE, WA--(Healthcare Sales & Marketing Network)--Aug 23, 2007 -- MitoPharm Corporation, Inc. (Other OTC:MTPM.PK ), a biotechnology company, today announces that one of the beneficial effects of Schisandrin B, the precursor of (-) Schisandrin B, is the protection of liver tissues.
The long exposure of the body to toxic substances, such as alcohol, dietary contaminants, and environmental pollutants, can damage the liver tissues, eventually leading to liver diseases such as cirrhosis and liver cancer.
Liver disease, while not as well known to the public as heart disease, is a significant national health problem due to the seriousness of its disorders and the numbers of people affected. According to statistics from the Centers for Disease Control and Prevention (CDC), it is the 9th leading cause of death in the United States, and studies suggest the death rates could triple during the next two decades.
Dr. Robert Ko, MitoPharm Corporation CSO, stated, "Schisandrin B, an active ingredient from Schisandra berry, has been shown to protect the liver against chemical toxin-induced damage. The investigation further uncovered a unique action mechanism of Schisandrin B in up-regulating the antioxidant defense in mitochondria, which are the powerhouse of the cells and, hence, indispensable for cell survival. By mopping up free radicals generated from the metabolism of toxic substances, the mitochondrial function is preserved, thereby preventing the cell death.
About MitoPharm
MitoPharm, Inc., www.mitopharm.com, is a biotechnology company that will operate in research & development, marketing, and sale of drugs, dietary supplements, and functional beverages. The initial products are based on a newly formulated compound, (-) Schisandrin B, that is the result of over 15 years of research and development by one of its founding shareholders, the Hong Kong University of Science and Technology.
Published scientific studies have confirmed that (-) Schisandrin B enhances the mitochondrial glutathione antioxidant status, a crucial factor in maintaining mitochondrial function and cell survival, plus it also induces the expression of Heat shock proteins, another group of important molecules for cell protection. These biochemical actions differentiate (-) Schisandrin B from other existing, known compounds, either synthetic or naturally occurring, in its ability to protect organs including the heart, the liver, and the brain.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations, are generally identifiable by the use of words such as "believe," "expect," "intend," "anticipate," "estimate," "project," or similar expressions. These forward-looking statements relate to, among other things, expectations of the business environment in which the Company operates, projections of future performance, potential future performance, perceived opportunities in the market, and statements regarding the Company's mission and vision. The Company's actual results, performance, and achievements may differ materially from the results, performance, and achievements expressed or implied in such forward-looking statements.
Source: MitoPharm
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
